Jane Street’s Syndax Pharmaceuticals SNDX Stock Holding History

Jane Street’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$778K	Sell	33,300 -13,300	-29%	-$289K	﹤0.01%	7047
2025 Q4	$979K	Buy	+46,600	New	+$813K	﹤0.01%	6169
2025 Q3	–	Sell	-10,600	Closed	-$99.3K	–	11697
2025 Q2	$99.3K	Buy	+10,600	New	+$117K	﹤0.01%	8952
2025 Q1	–	Sell	-506,000	Closed	-$6.69M	–	10525
2024 Q4	$6.69M	Buy	506,000 +447,600	+766%	+$7.66M	﹤0.01%	2309
2024 Q3	$1.12M	Buy	58,400 +14,900	+34%	+$308K	﹤0.01%	5647
2024 Q2	$893K	Buy	43,500 +9,000	+26%	+$188K	﹤0.01%	5974
2024 Q1	$821K	Sell	34,500 -75,000	-68%	-$1.67M	﹤0.01%	5758
2023 Q4	$2.37M	Sell	109,500 -209,000	-66%	-$3.21M	﹤0.01%	4032
2023 Q3	$4.62M	Buy	+318,500	New	+$6.02M	﹤0.01%	2715
2023 Q1	–	Sell	-15,000	Closed	-$382K	–	9858
2022 Q4	$382K	Sell	15,000 -900	-6%	-$21K	﹤0.01%	6611
2022 Q3	$382K	Buy	15,900 +500	+3%	+$11.2K	﹤0.01%	7184
2022 Q2	$296K	Buy	+15,400	New	+$257K	﹤0.01%	7627
2020 Q3	–	Sell	-12,300	Closed	-$182K	–	7860
2020 Q2	$182K	Buy	+12,300	New	+$187K	﹤0.01%	6430

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Jane Street's SNDX Position: Q1 2026 in Review

Jane Street reduced its Syndax Pharmaceuticals (SNDX) stake by 55% in Q1 2026, selling an estimated $8.98M and leaving 335,531 shares worth $7.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Jane Street first reported a position in SNDX in Q2 2020 and has held it in 18 quarters since. The position peaked at $15.7M in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Jane Street held 335,531 shares of Syndax Pharmaceuticals worth $7.84M as of Q1 2026.
Jane Street sold 413,389 Syndax Pharmaceuticals shares in Q1 2026, an estimated $8.98M.
Syndax Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2848 holding.
Jane Street first reported a position in Syndax Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
Jane Street's Syndax Pharmaceuticals position peaked at $15.7M in Q4 2025.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.